| Identification | Back Directory | [Name]
ARRY-380 | [CAS]
937265-83-3 | [Synonyms]
CS-523
Arry-830
ARRY-380
ARRY-380-d3
Arry-380, >=98%
HER2-Inhibitor-1
ARRY380; ARRY 380
ARRY-380 USP/EP/BP
ARRY-380 (analog )
ARRY-380;ARRY380; ARRY 380
6-[5-[[[2-(Methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-N-[3-methyl-4-([1,2,4]triazolo[1,5-a]
6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]-N-[3-methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]quinazolin-4-amine
N-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-Methylphenyl)-6-(5-(((2-(Methylsulfonyl)ethyl)aMino)Methyl)furan-2-yl)quinazolin-4-aMine
6-[5-[[[2-(Methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-N-[3-methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-4-quinazolinamine
4-Quinazolinamine, 6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-N-[3-methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-
6-[5-[[[2-(Methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-N-[3-methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-4-quinazolinamine ARRY 380 | [EINECS(EC#)]
813-083-0 | [Molecular Formula]
C29H27N7O4S | [MDL Number]
MFCD22420817 | [MOL File]
937265-83-3.mol | [Molecular Weight]
569.63 |
| Chemical Properties | Back Directory | [density ]
1.43 | [storage temp. ]
Store at -20°C | [solubility ]
≥28.5 mg/mL in DMSO; insoluble in EtOH; insoluble in H2O | [form ]
solid | [pka]
6.34±0.19(Predicted) | [color ]
Light brown to brown |
| Hazard Information | Back Directory | [Description]
Arry-380 analog was designed as an inhibitor of EGFR (ErbB1). | [Uses]
ARRY-380 is a potent and selective HER2 inhibitor with IC50 of 8 nM and also inhibits EGFR with IC50 of 4 μM. | [Uses]
Labelled ARRY-380. ARRY-380 is an orally bioavailable inhibitor of the human epidermal growth factor receptor tyrosine kinase ErbB-2. | [target]
p95-HER2 | [References]
[1] s. l. moulder, v. borges, s. k. l. chia, t. baetz, e. barrett, j. garrus, k. guthrie, c. kass, e. laird, j. lyssikatos, f. marmsater, e. wallace. arry-380, a selective her2 inhibitor: from drug design to clinical evaluation. poster of aacr-nci-eortc, nov 12-16, 2011, san francisco, ca.
[2] victoria dinkel, deborah anderson, shannon winski, jim winkler, kevin koch and patrice lee. arry-380, a potent, small molecule inhibitor of erbb2, increases survival in intracranial erbb2+ xenograft models in mice. poster available at www.arraybiopharma.com
[3] s. chia, t. baetz, s. d'aloisio, g. fernetich, b. freeman, e. barrett, c. kass, j. kang, b. sajan, s. moulder, and j. garrus. a phase 1 study to assess the safety, tolerability and pharmacokinetics of arry-380 – an oral inhibitor of her2. cancer res 2009;69(24 suppl):abstract nr 5111. |
|
| Company Name: |
NCE Biomedical Co.,Ltd.
|
| Tel: |
4000-027-021 |24 +86-13986109188 | +86-15623472865 | +81-08033611988 |
| Website: |
www.chemicalbook.com/ShowSupplierProductsList15748/0.htm |
|